

1 **Profiling cases with non-respiratory symptoms and asymptomatic SARS-CoV-2**
2 **infections in Mexico City**

3 Omar Yaxmehen Bello-Chavolla MD, PhD^{1*}, Neftali Eduardo Antonio-Villa MD², Arsenio
4 Vargas-Vázquez², Carlos A. Fermín-Martínez², Alejandro Márquez-Salinas², Jessica Paola
5 Bahena-López MD²

6
7 ¹Division of Research, Instituto Nacional de Geriátria. ²MD/PhD (PECEM), Faculty of
8 Medicine, National Autonomous University of Mexico.

9
10 **Short title:** Asymptomatic SARS-CoV-2 in Mexico City

11
12 **Corresponding author**

13 Omar Yaxmehen Bello-Chavolla. Division of Research. Instituto Nacional Geriátria. Anillo
14 Perif. 2767, San Jerónimo Lídice, La Magdalena Contreras, 10200, Mexico City, Mexico.
15 Phone: +52 (55) 5548486885. E-mail: oyaxbell@yahoo.com.mx

16 **CONFLICT OF INTERESTS:** Nothing to disclose.
17

18 **Word count:** 1,496 words; 2 Figures.

19 **ABSTRACT (50 WORDS)**

20 We profiled cases with non-respiratory symptoms (NRS) and asymptomatic SARS-CoV-2
21 assessed within Mexico City's Epidemiological Surveillance System. We show that initially
22 asymptomatic or NRS cases have decreased risk of adverse COVID-19 outcomes compared
23 to cases with respiratory symptoms. Comorbidity and age influence likelihood of developing
24 symptoms in initially asymptomatic cases.

25

26 **Keywords:** SARS-CoV-2; Asymptomatic; Pre-symptomatic; Mexico; COVID-19 outcomes

27

28 INTRODUCTION

29 Asymptomatic infections are a potential source of rapid SARS-CoV-2 spread¹. Prevalence of
30 pre-symptomatic/asymptomatic cases varies widely but represent a larger proportion of
31 cases than previously anticipated². Controversies surrounding asymptomatic SARS-CoV-2
32 infections have focused on the distinction between pre-symptomatic and asymptomatic
33 infection and its definitions; nevertheless, longitudinal data shows that only a fraction of
34 initially asymptomatic infections develop subsequent symptoms^{3,4}. In Mexico, SARS-CoV-2
35 testing focuses on sampling high-risk cases with suspected COVID-19 by the presence of
36 RS, which has allowed characterization of increased susceptibility for severe COVID-19
37 attributable to cardio-metabolic comorbidities⁵; however, no data has been reported on cases
38 with non-respiratory symptomatology (NRS) and asymptomatic SARS-CoV-2 infections,
39 which are underrepresented under the current testing framework in Mexico. Lack of
40 information regarding cases with NRS, or initially asymptomatic cases in Mexico is
41 concerning, particularly since many studies suggest that contact tracing of asymptomatic
42 infections will be pivotal to contain further SARS-CoV-2 spread and the likelihood of
43 underreporting cases without respiratory symptoms but with NRS⁶. Here, we profile patients
44 with NRS and initially asymptomatic SARS-CoV-2 infections to assess outcomes after follow-
45 up using cases detected in Mexico City.

46 METHODS

47 We analyzed data from the National Epidemiological Surveillance System in the Greater
48 Mexico City area, an open-source dataset comprising daily updated cases tested using real-
49 time RT-PCR to confirm SARS-CoV-2 using nasopharyngeal swabs according to the Berlin
50 Protocol⁷. For analysis, we propose two main symptom groups, which we confirmed using
51 correspondence analyses to cluster symptoms with comparable similarity (**Supplementary**
52 **Material**): RS included dyspnea, polypnea or cyanosis at initial evaluation, but we also
53 included fever and cough in this group based on WHO criteria for suspected COVID-19

54 cases; whilst NRS included headache, myalgias, arthralgias, general malaise, abdominal
55 pain, chest pain, conjunctivitis, irritability or vomiting. We defined cases with RS as those with
56 ≥ 1 RS and any or none NRS. Cases with NRS had ≥ 1 NRS without any RS, whilst initially
57 asymptomatic cases had no symptoms at the point of initial assessment. NRS and initially
58 asymptomatic cases were assessed outside the established framework for suspected
59 COVID-19 cases in Mexico by contact tracing of real-time RT-PCR confirmed SARS-CoV-2
60 infection and convenience sampling of cases without symptoms who requested an RT-PCR
61 test for SARS-CoV-2; complete description of the Mexican testing framework is described in
62 **Supplementary Material**. We also estimated 7-day rolling average positivity rates (PR) for
63 RS, NRS and initially asymptomatic cases. Follow-up was conducted for all non-hospitalized
64 cases up to 14 days; outcomes for all patients included hospital discharge due to clinical
65 improvement or voluntary, ambulatory/treatment follow-up or death; additional information
66 regarding follow-up is presented in **Supplementary Material**. Severe COVID-19 was defined
67 as a composite of death, ICU admission or intubation. Complete description of statistical
68 analyses and available variables are detailed in **Supplementary Material**.

69 **RESULTS**

70 Study population

71 As of 19th August 2020, a total of 296,157 subjects were tested for SARS-CoV-2 in Mexico
72 City. From 108,080 cases with confirmed SARS-CoV-2 infection (PR 36.5%), 14,657 cases
73 did not have RS (13.6%). Overall, 37,356 NRS cases had been evaluated, amongst whom
74 8,545 had confirmed SARS-CoV-2 infection (Overall PR: 22.9%); similarly, 35,175 initially
75 asymptomatic cases were evaluated and 6,112 cases had confirmed SARS-CoV-2 infection
76 (PR: 17.4%). Seven-day PRs had been steadily decreasing for all patient categories during
77 the last few weeks (**Supplementary Material**). NRS cases were younger, predominantly
78 female and had lower prevalence of NRS compared to cases with RS. Initially asymptomatic

79 cases were younger compared to RS cases, with similar trends for lower rates of
80 comorbidities compared to both RS and NRS cases (**Figure 1**).

81 Profiling NRS cases with SARS-CoV-2 infection

82 Amongst NRS cases (n=8,545), 365 subjects were hospitalized (4.3%), 32 required
83 mechanical ventilatory support (MVS) (0.4%), 32 required intensive care unit (ICU) admission
84 (0.4%). Overall, 112 patients died (1.3%), of whom 24 deaths were ambulatory (0.3%) and 88
85 hospitalized (1.0%). Predictors that increased risk for severe COVID-19 in NRS cases
86 included age >60 years, chronic obstructive pulmonary disease (COPD), diabetes, and
87 chronic kidney disease (CKD); decreased risk of severe COVID-19 was associated with
88 rhinorrhea, previous exposure to suspected viral cases and healthcare workers. Independent
89 predictors of mortality in NRS included age >60 years, diabetes, COPD, CKD, and decreased
90 risk associated with previous exposure to suspected viral cases (**Supplementary Material**).
91 After follow-up, 530 patients were still under domiciliary surveillance (6.2%), 127 remained
92 hospitalized (1.5%), 146 were discharged after recovery (1.7%), 4 had voluntary discharge
93 and 7,626 had completed follow-up with domiciliary surveillance without developing RS
94 (89.2%).

95 Profiling initially asymptomatic cases with SARS-CoV-2 infection

96 Amongst initially asymptomatic patients with SARS-CoV-2 infection (n=6,112), 185 were
97 eventually hospitalized (3.0%), 12 required MVS (0.2%) and 29 required ICU admission
98 (0.5%). We recorded 32 deaths (0.5%) amongst whom 11 deaths were ambulatory (0.2%)
99 and 21 were hospitalized (0.3%). Predictors for severe COVID-19 included age >60 years,
100 CKD, and reduced risk associated to previous exposure to suspected viral cases; predictors
101 of lethality included age >60 years and CKD. As of August 19th 2020, 415 patients were still
102 under domiciliary surveillance (6.8%), 91 remained hospitalized (1.5%), 71 were discharged
103 after recovery (1.2%), 2 had a voluntary discharge, and 5,501 had completed follow-up
104 without developing symptoms which required hospitalization (90.0%).

105 *Predictors and outcomes for RS, NRS and asymptomatic cases*

106 Compared to initially asymptomatic cases, symptomatic cases were associated with older
107 age, reduced previous viral exposure, healthcare workers, diabetes, obesity, hypertension,
108 CKD, COPD, asthma and smoking. Similarly, compared to NRS, RS cases were associated
109 with asthma, immunosuppression, COPD, older age, male sex, diabetes, obesity,
110 hypertension, reduced previous viral exposure with a reduced likelihood associated with
111 smoking (**Figure 2**). Compared to initially asymptomatic cases, risk of severe COVID-19 was
112 significantly higher for both NRS (HR 1.56, 95%CI 1.14-2.13) and RS cases (HR 4.78, 95%CI
113 3.67-6.21), adjusted for age, sex and comorbidities. Similarly, NRS and RS had higher
114 mortality compared to asymptomatic cases (Breslow-Cox $p < 0.001$, **Figure 2**); adjusting for
115 age, sex and comorbidities, NRS (HR 2.32, 95%CI 1.57-3.43) or RS cases (HR 6.50, 95%CI
116 4.59-9.21) retained higher mortality compared to initially asymptomatic cases.

117 **DISCUSSION**

118 Here, we present a comprehensive report of COVID-19 cases with NRS and initially
119 asymptomatic SARS-CoV-2 infections in Mexico City. Early detection of SARS-CoV-2
120 infections in initially asymptomatic patients or who present with NRS would help to reduce the
121 spread of SARS-CoV-2 in Mexico, as these patients have lower risk of subsequent
122 complications, as shown in this study, and would benefit the most from domiciliary treatment
123 and prompt isolation. We also report a low prevalence of cases who were initially classified as
124 asymptomatic but eventually were hospitalized or had outcomes related to severe COVID-
125 19⁸. This data confirms observations from other populations regarding the course of COVID-
126 19 cases with NRS and initially asymptomatic SARS-CoV-2 infections³. Our study also
127 highlights the relevance of extending testing to cases with NRS and initially asymptomatic
128 cases within the testing framework in Mexico; identifying asymptomatic cases is of
129 importance given conflicting evidence on viral shedding for these cases, and data suggesting
130 evidence of subclinical lung abnormalities which must be assessed longitudinally to rule out

131 long-term impacts of SARS-CoV-2 infection⁹. Notably, a consistent predictor of outcomes for
132 NRS cases and initially asymptomatic cases were previous exposure to suspected viral
133 cases, highlighting the relevance of contact tracing and prompt case identification but also
134 confirming that cases presented in our study are not representative of all asymptomatic
135 infections but mostly of those identified by contact tracing, likely underestimating rates of true
136 asymptomatic cases.

137 Studies assessing natural history of initially asymptomatic SARS-CoV-2 infections highlighted
138 the role of age and comorbidity in the subsequent development of symptoms, which is
139 consistent with our observations¹⁰. Domiciliary surveillance in Mexico City focused on
140 outcomes but not individual symptom onset, which might limit our ability to adequately
141 characterize pre-symptomatic cases, particularly those who only develop mild symptoms and
142 do not require hospital admission. Regardless, only a small fraction of initially asymptomatic
143 cases developed severe COVID-19 after initial assessment, most of whom had underlying
144 chronic comorbidities or were susceptible for COVID-19 complications attributable to
145 unmasked cardiometabolic comorbidities. The eventual presentation of severe COVID-19 in
146 initially asymptomatic cases might be attributable to a combination of decreased early
147 immune response to SARS-CoV-2 infection and late enhanced pro-inflammatory responses
148 in subjects with comorbidities^{9,11}. This might also extend to subjects with NRS with COVID-
149 19 whom have previously been reported to delay seeking medical attention and have
150 prolonged viral shedding compared with subjects with RS only¹².

151 Here, we assessed a thorough constellation of symptoms in one of the largest studies of NRS
152 and initially asymptomatic SARS-CoV-2 infections. Additional limitations include non-
153 assessment of atypical SARS-CoV-2 symptoms which might occur amongst otherwise
154 asymptomatic cases, particularly in older adults, and the lack of systematized sampling,
155 which does not allow for an accurate estimation for the rates of asymptomatic cases in
156 Mexico City. Our results highlight the need to systematize definitions of asymptomatic cases

157 and extend testing by contact tracing to detect asymptomatic SARS-CoV-2 infections as one
158 of the mitigations strategies to reduce transmission of SARS-CoV-2 in Mexico City and
159 Mexico in general.

160

161 **ACKNOWLEDGMENTS**

162 NEAV, JPBL, and AVV are enrolled at the PECEM program of the Faculty of Medicine at
163 UNAM. JPBL and AVV are supported by CONACyT. The authors would like to acknowledge
164 the invaluable work of all of Mexico's healthcare community in managing the COVID-19
165 epidemic. Its participation in the COVID-19 surveillance program has made this work a reality,
166 we are thankful for your effort.

167 **DATA AVAILABILITY**

168 All data sources and R code are available for reproducibility of results at
169 https://github.com/oyaxbell/covid_asymptomatic_cdmx.

170 **AUTHOR CONTRIBUTIONS**

171 Research idea and study design OYBC, NEAV, AVV, JPBL, CAFM, AMS; data acquisition:
172 OYBC; data analysis/interpretation: OYBC, JPBL, NEAV, AVV, CAFM, AMS; statistical
173 analysis: OYBC; manuscript drafting: OYBC, NEAV, AVV, JPBL, CAFM, AMS; supervision or
174 mentorship: OYBC. Each author contributed important intellectual content during manuscript
175 drafting or revision and accepts accountability for the overall work by ensuring that questions
176 about the accuracy or integrity of any portion of the work are appropriately investigated and
177 resolved.

178 **FUNDING:** This project was supported by a grant from Secretaría de Educación, Ciencia,
179 Tecnología e Innovación de la Ciudad de México CM-SECTEI/041/2020 “Red Colaborativa
180 de Investigación Traslacional para el Envejecimiento Saludable de la Ciudad de México
181 (RECITES)”.


182 **CONFLICT OF INTEREST/FINANCIAL DISCLOSURE:** Nothing to disclose.

184 **REFERENCES**

- 185 1. Buitrago-Garcia DC, Egli-Gany D, Counotte MJ, et al. The role of asymptomatic SARS-
186 CoV-2 infections: rapid living systematic review and meta-analysis. *medRxiv*. April
187 2020. doi:10.1101/2020.04.25.20079103
- 188 2. Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative
189 Review. *Ann Intern Med*. June 2020. doi:10.7326/M20-3012
- 190 3. Sakurai A, Sasaki T, Kato S, et al. Natural History of Asymptomatic SARS-CoV-2
191 Infection. *N Engl J Med*. June 2020. doi:10.1056/NEJMc2013020
- 192 4. Imperial College COVID-19 Response Team, Lavezzo E, Franchin E, et al. Suppression
193 of a SARS-CoV-2 outbreak in the Italian municipality of Vo. *Nature*. June 2020.
194 doi:10.1038/s41586-020-2488-1
- 195 5. Bello-Chavolla OY, Bahena-López JP, Antonio-Villa NE, et al. Predicting mortality due
196 to SARS-CoV-2: A mechanistic score relating obesity and diabetes to COVID-19
197 outcomes in Mexico. *J Clin Endocrinol Metab*. May 2020. doi:10.1210/clinem/dgaa346
- 198 6. Huff HV, Singh A. Asymptomatic transmission during the COVID-19 pandemic and
199 implications for public health strategies. *Clin Infect Dis*. May 2020.
200 doi:10.1093/cid/ciaa654
- 201 7. Covid-19 SINAVE Ciudad de México — Datos CDMX.
202 <https://datos.cdmx.gob.mx/explore/dataset/base-covid-sinave/table/>. Accessed June 28,
203 2020.
- 204 8. Meng H, Xiong R, He R, et al. CT imaging and clinical course of asymptomatic cases
205 with COVID-19 pneumonia at admission in Wuhan, China. *J Infect*. 2020;81(1):e33-e39.
206 doi:10.1016/j.jinf.2020.04.004
- 207 9. Long Q-X, Tang X-J, Shi Q-L, et al. Clinical and immunological assessment of
208 asymptomatic SARS-CoV-2 infections. *Nat Med*. June 2020. doi:10.1038/s41591-020-
209 0965-6
- 210 10. [2006.08471] Probability of symptoms and critical disease after SARS-CoV-2 infection.
211 <https://arxiv.org/abs/2006.08471>. Accessed June 28, 2020.
- 212 11. Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS-CoV-2 and mechanisms
213 of immunopathological changes in COVID-19. *Allergy*. May 2020. doi:10.1111/all.14364
- 214 12. Han C, Duan C, Zhang S, et al. Digestive Symptoms in COVID-19 Patients With Mild
215 Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes. *Am J*
216 *Gastroenterol*. 2020;115(6):916-923. doi:10.14309/ajg.0000000000000664



217

218 **FIGURE LEGENDS**



219 **FIGURE 1.** Histogram comparing case distribution according to age groups comparing cases with RS, NRS and asymptomatic
 220 SARS-CoV-2 infection, demonstrating the role of age in determining asymptomatic SARS-CoV-2 infections (A). We also show a
 221 comparison of the distribution of NRS related to SARS-CoV-2 infections in subjects with RS and NRS only. * $p < 0.001$
 222 Abbreviations: RS: Respiratory symptoms; NRS: Non-respiratory Symptoms; Sudden onset: Patient report of sudden onset of
 223 symptomatology.

224
 225
 226



227

228 **FIGURE 2.** Factors associated with presence of RS compared to NRS, and RS/NRS compared to asymptomatic cases with SARS-
 229 CoV-2 infection (A). We also show the and comparison of 30-day mortality rates between RS cases, NRS and asymptomatic SARS-
 230 CoV-2 infections in Mexico City (B).

231 Abbreviations: RS: Respiratory symptoms; NRS: Non-respiratory Symptoms; COPD: Chronic obstructive pulmonary disease; CKD:
 232 Chronic kidney disease; HCW: Health-care workers; Previous viral exposure: Prior contact with a patient with suspected viral
 233 infection.